Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid...

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic inflammatory disease.
• Methotrexate is a common RA treatment, but some patients have inadequate response.
• Filgotinib is a preferential Janus kinase (JAK) 1 inhibitor evaluated in RA.

Purpose of the Study:

• To evaluate protein biomarker changes in RA patients treated with filgotinib.
• To assess the impact of filgotinib on JAK/STAT signaling, inflammation, and bone resorption.
• To compare filgotinib's biomarker effects to adalimumab and placebo.

Main Methods:

• Phase 3 FINCH 1 trial data (NCT02889796) were analyzed.
• Patients with active RA and inadequate response to methotrexate received filgotinib, adalimumab, or placebo.
• Plasma and serum samples were analyzed for up to 35 biomarkers at baseline, week 4, and week 12.

Main Results:

• Four distinct biomarker clusters were identified at baseline, correlating with inflammation and JAK/STAT signaling.
• Filgotinib reduced inflammatory cytokines and cell migration biomarkers by week 4.
• Filgotinib showed greater reductions in bone turnover biomarkers compared to adalimumab.

Conclusions:

• Filgotinib demonstrated dose-dependent reductions in peripheral biomarkers related to JAK/STAT signaling, inflammation, and bone resorption.
• These biomarker changes were observed as early as week 4 and were consistent with clinical efficacy.
• The effects of filgotinib on biomarkers in methotrexate-experienced patients were similar to those in other RA populations.